Straumann Holding AG: insider trades · Switzerland · SIX SER

About Straumann Holding AG

Straumann Holding AG is a leading global player in dental implantology and orthodontic solutions. Listed on the SIX Swiss Exchange (SMI/SPI) in Switzerland, the company offers investors a defensive healthcare profile with growth supported by innovation, demographic aging, and rising oral-care demand. Headquartered in Basel, Switzerland, Straumann was founded in 1954 and has evolved into an international reference in tooth replacement and aesthetic dentistry. ([straumann.com](https://www.straumann.com/us/en/dental-professionals/about/the-straumann-group.html?utm_source=openai)) The group operates across several complementary business lines: implantology, prosthetics, biomaterials, digital solutions, and orthodontics. Its portfolio includes the Straumann, Neodent, Medentika, Anthogyr, and ClearCorrect brands, along with technology partnerships and digital workflow tools. This broad offering allows the company to cover a significant part of the treatment chain, from implants to CAD/CAM restorations, guided surgery, intra-oral scanning, and clear aligners. ([straumann.com](https://www.straumann.com/group/en/home/about/contact-us/contact-our-brands.html?utm_source=openai)) From a competitive standpoint, Straumann stands out through strong scientific credibility, a broad global distribution network, and close relationships with dental professionals, laboratories, and dental service organizations. The group says its products, solutions, and services are available in more than 100 countries, giving it a highly diversified geographic footprint. Its strategy is built around clinical education, product innovation, manufacturing quality, and the gradual integration of digital technologies into treatment workflows. ([straumann.com](https://www.straumann.com/us/en/dental-professionals/about/the-straumann-group.html?utm_source=openai)) Recent developments point to continued operational momentum. The 2024 and 2025 disclosures highlight solid commercial trends, market-share gains, strategic execution improvements, and further progress in digital offerings. Straumann also continued to streamline its portfolio, including the divestment of DrSmile, in order to focus resources on its core businesses with the strongest conviction. Full-year 2025 results, published in early 2026, indicated continued organic growth and strategic progress despite a more volatile macroeconomic and geopolitical backdrop. ([straumann.com](https://www.straumann.com/group/en/discover/annualreport/2024.html?utm_source=openai)) For francophone investors, Straumann combines exposure to a structurally attractive dental healthcare market with strong brand leadership and innovation potential, while remaining sensitive to foreign exchange movements, discretionary demand in certain segments, and commercial execution in key geographies.